Hydronidone for the Treatment of Liver Fibrosis Associated With Chronic Viral Hepatitis B Phase 3 Trial.
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This study was a randomized, double-blind, placebo-controlled, entecavir basic treatment,
multicentre clinical study.
The main objective of this study was to confirm the efficacy and safety of hydronidone in the
treatment of chronic hepatitis B liver fibrosis.